We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

PacBio Announces Revio, a Revolutionary New Long Read Sequencing System

The PacBio Revio system on a black background.

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "PacBio Announces Revio, a Revolutionary New Long Read Sequencing System"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

PacBio (NASDAQ: PACB) has announced the Revio™ long-read sequencing system, which will enable customers to dramatically scale their use of PacBio’s celebrated HiFi sequencing technology. Revio is designed to provide customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage for less than $1,000 per genome. With this scale and pricing, PacBio believes Revio will enable the use of HiFi sequencing for large studies in human genetics, cancer research, agricultural genomics, and more.

 

“Our customers have transformed genomics with the power of HiFi sequencing. Revio will further unleash that power by adding high throughput and affordability,” said Christian Henry, President and Chief Executive Officer of PacBio. “We’ve designed an entirely new SMRT Cell with three-fold higher density than our existing SMRT Cell 8M, resulting in 25 million ZMWs. Revio will run up to four SMRT Cells in parallel, which provides up to 100 million ZMWs for sequencing single molecules simultaneously. Combined with significant advances in our compute, Revio will deliver shorter run times and a 15-fold increase in HiFi data. I’m excited to see what researchers can discover using the power of Revio.”

 

Scientists have achieved many ‘firsts’ with HiFi sequencing on PacBio’s Sequel IIe sequencing system – the first complete telomere-to-telomere assembly of a human genome (Nurk 2022), the first haplotype-resolved methylomes in a rare disease cohort (Cheung 2022), the first population surveys of structural variation with long reads (All of Us Research Program), the first single-cell full isoform catalogs (Al'Khafaji 2021), and the first complete assembly of the highly complex oat genome (European Seed 2020). Revio uses the same groundbreaking HiFi chemistry – producing accurate native long reads with uniform coverage, extraordinary application performance for variant calling and assembly, and accurate DNA methylation detection – but at a much larger scale.

Revio will be PacBio’s first system to feature state-of-the-art NVIDIA GPUs, providing a 20-fold increase in computing power compared to the Sequel IIe. In addition to providing accelerated basecalling to meet Revio’s higher throughput, the AI-enabled compute will integrate deep learning algorithms to detect DNA methylation from standard sequencing libraries, and DeepConsensus, a deep learning method developed with Google Health to improve the yield and accuracy of HiFi sequencing.

 

Revio will require 50 percent fewer consumables than the Sequel IIe and includes substantial improvements in workflow and convenience. Revio will make it possible to set up a subsequent run while the current run is in progress, which provides increased schedule flexibility for an operator to load runs any time of day and maximize system throughput.

 

“In our Genomic Answers For Kids (GA4K) program, HiFi genome sequencing shows true advancement beyond contemporary genetic analysis in unsolved rare disease samples,” said Tomi Pastinen, MD, PhD, Director of the Genomic Medicine Center at Children’s Mercy Kansas City. “Increased throughput of the Revio sequencing system at lower cost would accelerate answers in GA4K.”

 

“The new Revio sequencing system from PacBio will be a key component in our genomics toolbox at Corteva. Long-read sequencing has enabled the characterization of complex plant genomes and now the high-throughput capabilities of Revio will allow us to apply HiFi technology to a wider array of applications in agricultural biotechnology,” said Gina Zastrow-Hayes, Biotechnology and GT-Genomics Technology Manager at Corteva Agriscience.

 

Revio has a list price of US $779,000. PacBio is now accepting orders and intends to begin delivery in the first quarter of 2023.

 

PacBio has also posted a presentation to its website with additional details about Revio. Interested parties can access the presentation on PacBio’s Investor Relations website, here and product information here.

Advertisement